Natera (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced their collaboration on the MiRaDoR (NCT05708235) study.
This multicenter, Phase II clinical trial will evaluate the efficacy of various therapeutic approaches in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer, a disease that represents approximately 70% of all breast cancer cases worldwide.
Breast cancer remains the most common cancer in women globally, with around 2.3 million new cases diagnosed in 2022.
Despite advancements in treatment, recurrence continues to be a significant concern for HR+/HER2- patients.
The MiRaDoR study, funded by F. Hoffman-La Roche Ltd. and sponsored by MEDSIR, will use Natera’s Signatera Genome to assess the effectiveness of different therapeutic strategies in early-stage HR+/HER2- breast cancer.
The trial will enroll up to 60 patients who are Signatera-positive but show no clinical or radiological evidence of disease recurrence.